# A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD

> **NCT02815488** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 118 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** CHF6297 (Part 1 - SAD)
- **DRUG:** Placebo (Part 1 - SAD)
- **DRUG:** CHF6297 (Part 2 - MAD)
- **DRUG:** Placebo (Part 2 - MAD)
- **DRUG:** CHF6297 (Part 3)
- **DRUG:** Placebo (Part 3)
- **DRUG:** CHF6297 (Part 4)
- **DRUG:** Placebo (Part 4)

## Key facts

- **NCT ID:** NCT02815488
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-22
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 118 (ACTUAL)
- **Why stopped:** Very poor recruitment in the Part 4 of the study
- **Last updated:** 2020-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02815488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02815488, "A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02815488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*